The gastric motility disorder drug market is estimated to be valued at USD 57.65 Bn in 2024 and is expected to reach USD 83.15 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
To learn more about this report, request sample copy
The market is experiencing positive growth due to the increasing prevalence of gastric motility disorders worldwide. Various factors such as the growing geriatric population, changing lifestyle habits, and dietary changes are contributing to the rising cases of gastric disorders. Moreover, the ongoing development of novel and advanced drugs for the treatment of gastric motility disorders is further supporting the market growth. However, the expiry of patents of major drugs and stringent regulations for drug approval may hamper the market growth during the forecast period.
Rising incidence of gastric disorders
The global prevalence of gastric motility disorders has been increasing steadily over the past few decades. Various factors such as changing lifestyle patterns, unhealthy diets, and higher levels of stress have significantly contributed to the rising incidence of gastric issues across both developing and developed regions. People are leading increasingly hurried and stressful lives which is negatively impacting the functioning of their digestive system. Additionally, certain medical conditions like diabetes, neurological disorders, and gastric surgeries can predispose patients to developing gastric motility dysfunction over time. The growing patient pool of chronic gastric disorders indicates a growing need for more effective treatment options. Currently available medications are often found to produce unsatisfactory results or come with intolerable side-effects in many cases.
Another important driver for the gastric motility drug market is the steadily ageing population worldwide. Advances in public healthcare have contributed to increased life expectancy which means the proportion of elderly individuals is growing in most countries and regions. This phenomenon has significant implications for the healthcare industry since the risk of developing gastric motility issues rises considerably with age. The elderly tend to experience higher rates of comorbidities like Parkinson's disease, diabetes, and arthritis - all of which can potentially impair normal stomach function over time. Age-related decline in lean muscle mass and immunity also renders older patients more prone to experiencing gastric emptying problems, nausea, vomiting, and discomfort after meals.
Gastric Motility Disorder Drug Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients